RESUMO
This methodology is proposed to measure the fluxes of trace gases among microcosms and the atmosphere. As microcosm respiration we include both aerobic and anaerobic respiration, which may results in CO2, CH4, NO, N2O, N2, H2S and H2 fluxes. Its applicability includes the assessment of products biodegradability and toxicity, the effect of treatments and products on greenhouse gases fluxes, and the mineralization of organic fertilizers. A step by step procedure; the complementary parameters and good practices that might be taken into account to perform a microcosm experiment; and the tools nowadays available that could be useful in this respirometric methodology are presented. We included a spreadsheet with calculus examples. Samples were taken at 1; 30; 60 and 90â¯min after closing the microcosms to determine the gases fluxes. The dilution effect was negligible, as we present. Besides CO2, we have successfully quantified the fluxes of CH4 and N2O from the microcosms in a broad range of concentrations. This method is useful in technical and scientific studies, for instances to test new products and improve the understanding of microbial processes, respectively. â¢Simple materials are required to set up the microcosm.â¢Examples of (pre) treatments are given regarding water availability, fertilizer doses, pH adjustment and nutrients amendments.â¢The method was suitable to directly measure multiple trace gases fluxes, either produced or consumed during microcosm respiration.
RESUMO
Growth disorders are commonly observed in children suffering from chronic diseases. The pathogenesis of growth failure is multifactorial. In chronic inflammatory diseases such as juvenile idiopathic arthritis and inflammatory bowel disease, growth is also affected by pro-inflammatory cytokines. Patients with chronic diseases might also become growth hormone (GH) deficient. However, normal or increased GH secretion with reduced plasma concentrations of insulin-like growth factor-I indicate a degree of GH insensitivity in some patients. Growth damage can increase with specific treatments, especially if glucocorticoids are used. GH therapy has been used to reduce the consequences of the disease and long-term steroid therapy in these patients. In this review, it is reported the encouraging results of GH treatment in growth-retarded children with chronic diseases, both in well defined indications as well in situations still under investigation.
Assuntos
Transtornos do Crescimento/tratamento farmacológico , Hormônio do Crescimento Humano/uso terapêutico , Doenças Inflamatórias Intestinais , Estatura/efeitos dos fármacos , Criança , Doença Crônica , Citocinas/fisiologia , Nanismo/tratamento farmacológico , Nanismo/etiologia , Transtornos do Crescimento/etiologia , Humanos , Doenças Inflamatórias Intestinais/complicações , Doenças Inflamatórias Intestinais/fisiopatologiaRESUMO
Crianças com doenças crônicas freqüentemente apresentam crescimento inadequado e baixa estatura. A falência do crescimento é multifatorial. Nas doenças inflamatórias, como na artrite juvenil idiopática e nas doenças inflamatórias intestinais, o crescimento é comprometido também pelo processo inflamatório. Muitas vezes, o tratamento da doença de base compromete o crescimento, especialmente quando é necessário glicocorticóides. Em algumas situações é possível comprovar a deficiência associada de hormônio de crescimento (GH, do inglês growth hormone). Em outras, os exames sugerem certo grau de insensibilidade ao GH. O tratamento destes pacientes com GH tem se mostrado útil e seguro com melhora do crescimento e da qualidade de vida. Nesta revisão, são apresentados resultados do tratamento com GH em pacientes com baixa estatura decorrente de doenças crônicas, algumas indicações já bem definidas e outras ainda em investigação.
Growth disorders are commonly observed in children suffering from chronic diseases. The pathogenesis of growth failure is multifactorial. In chronic inflammatory diseases such as juvenile idiopathic arthritis and inflammatory bowel disease, growth is also affected by pro-inflammatory cytokines. Patients with chronic diseases might also become growth hormone (GH) deficient. However, normal or increased GH secretion with reduced plasma concentrations of insulin-like growth factor-I indicate a degree of GH insensitivity in some patients. Growth damage can increase with specific treatments, especially if glucocorticoids are used. GH therapy has been used to reduce the consequences of the disease and long-term steroid therapy in these patients. In this review, it is reported the encouraging results of GH treatment in growth-retarded children with chronic diseases, both in well defined indications as well in situations still under investigation.